Thu, Mar 28, 2024
A A A
Welcome Guest
Free Trial RSS pod
Get FREE trial access to our award winning publications
Alternative Market Briefing

PIPE investors look to healthcare, biotech and financial services for opportunity

Wednesday, September 30, 2009

From Kirsten Bischoff, Opalesque New York:

Private investments in public equity (PIPE) managers expect to maintain the level at which they are currently investing in, or increase their investment activity over the next 12 to 18 months, according to a new survey by Kramer Levin Naftalis & Frankel LLP and Rodman & Renshaw LLC, and released by MergerMarket.

The firms, which surveyed US PIPE investors including private equity managers, venture capital investors, hedge fund managers and mutual fund investors, will also look overwhelmingly towards the lower mid-market range for opportunities. Over half of all the respondents expect PIPE demand to see its greatest demands within the healthcare, biotechnology and life sciences industry.

"The resurgence of the biotechs is because for an extended period of time the credit markets tightened up and many of the stocks in this sector were so depressed that even if they could get PIPE financing they didn't want it," Reid Drescher, Founder and Portfolio Manager at New York-based Cape One Financial which manages a PIPE hedge fund. The return of market liquidity as well as rising market caps have brought a resurgence of transactions within this space.

In addition to rising levels of activity in the biotech sector, Drescher has also seen an incre......................

To view our full article Click here

Previous Opalesque Exclusives                                  
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. KKR raises $6.4bn for the largest pan-Asia infrastructure fund[more]

    Laxman Pai, Opalesque Asia: The New York-based global investment firm KKR has raised a record $6.4bn for its second Asia-focused infrastructure fund, underlining investors' continued appetite for private markets. According to a media release from the alternative assets manager, the figure top

  2. Bucking the trend, top hedge fund makes plans for a second SPAC[more]

    From Institutional Investor: SPACs aren't dead. At least not to the folks at Cormorant Asset Management. The life sciences firm, whose hedge fund topped its peers in 2023, is confident it will match the success of its first blank-check company. Last week, the life sciences and biopharma speciali

  3. Benefit Street Partners closes fifth fund on $4.7 billion[more]

    Bailey McCann, Opalesque New York: Benefit Street Partners has closed its fifth flagship direct lending vehicle, BSP Debt Fund V, with $4.7 billion of investable capital across the strategy. Benefit Street invests primarily in privately originated, floating rate, senior secured loans. The fun

  4. 4 hedge fund themes that are working in 2024[more]

    From The Street: A poor earnings report from Tesla (TSLA) has not hurt the indexes on Thursday. The decline in Tesla stock, which is losing its position in the Magnificent Seven pantheon, is more than offset by strong earnings from IBM (IBM) and ServiceNow (NOW) . In addition, the much higher-t

  5. Opalesque Exclusive: A global macro fund eyes opportunities in bonds[more]

    Bailey McCann, Opalesque New York for New Managers: Munich-based ThirdYear Capital rebounded in 2023, following a tough year for global macro. The firm's flagship ART Global Macro strategy finished the year up 1